The PE Ratio as of December 2024 (TTM) for Avidity Biosciences, Inc. (RNA) is -10.99

According to Avidity Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.99. This represents a change of -1.02% compared to the average of -11.10 of the last 4 quarters.

Avidity Biosciences, Inc. (RNA) Historical PE Ratio (quarterly & annually)

How has RNA PE Ratio performed in the past?

The mean historical PE Ratio of Avidity Biosciences, Inc. over the last ten years is -18.93. The current -10.99 PE Ratio has changed 5.70% with respect to the historical average. Over the past ten years (40 quarters), RNA's PE Ratio was at its highest in in the September 2023 quarter at -2.26. The PE Ratio was at its lowest in in the March 2019 quarter at -57.81.

Avidity Biosciences, Inc. (RNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Avidity Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Avidity Biosciences, Inc. (RNA) Average PE Ratio

How has RNA PE Ratio performed in the past?

The current PE Ratio of Avidity Biosciences, Inc. (RNA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Avidity Biosciences, Inc. (RNA) PE Ratio vs. Peers

How is RNA’s PE Ratio compared to its peers?

Avidity Biosciences, Inc.’s PE Ratio is less than TCR2 Therapeutics Inc. (-0.38), greater than Revolution Medicines, Inc. (-12.93), less than Black Diamond Therapeutics, Inc. (-1.69), less than Atreca, Inc. (-0.06), less than Passage Bio, Inc. (-0.58), less than Akero Therapeutics, Inc. (-8.30), less than Protagonist Therapeutics, Inc. (14.68), less than Stoke Therapeutics, Inc. (-6.20), less than IGM Biosciences, Inc. (-1.80), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), less than Cullinan Oncology, Inc. (-4.82), less than Mineralys Therapeutics, Inc. (-3.92), greater than Day One Biopharmaceuticals, Inc. (-14.55), less than SpringWorks Therapeutics, Inc. (-10.09), less than Relay Therapeutics, Inc. (-1.76), less than Pliant Therapeutics, Inc. (-4.02), less than Arvinas, Inc. (-4.21),

Build a custom stock screener for Avidity Biosciences, Inc. (RNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avidity Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Avidity Biosciences, Inc. (RNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Avidity Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.